38 results
10-K
2023 FY
EX-10.22
NMRA
Neumora Therapeutics Inc.
7 Mar 24
Annual report
4:05pm
under the Company’s conflict of interest policies. For the avoidance of doubt, the CEO has approved Executive’s continued service with those … of conflict or raises a conflict under the Company’s conflict of interest policies.
2.Term. The period of Executive’s employment under this Agreement
10-K
2023 FY
EX-10.23
NMRA
Neumora Therapeutics Inc.
7 Mar 24
Annual report
4:05pm
the Company’s conflict of interest policies. For the avoidance of doubt, the CEO has approved Executive’s continued employment or service with those
10-K
2023 FY
NMRA
Neumora Therapeutics Inc.
7 Mar 24
Annual report
4:05pm
and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable foreign regulatory
8-K
EX-3.2
NMRA
Neumora Therapeutics Inc.
19 Sep 23
Amendments to Articles of Incorporation or Bylaws
4:16pm
as a director of the Corporation, will comply with all applicable corporate governance, conflict of interest, confidentiality, stock ownership and trading
424B4
e0soap6u11djf y8
18 Sep 23
Prospectus supplement with pricing info
4:12pm
S-1/A
op4nd
11 Sep 23
IPO registration (amended)
6:07am
S-1/A
EX-10.13
i33uvhf12
11 Sep 23
IPO registration (amended)
6:07am
S-1
EX-2.1
9pt79r8b
25 Aug 23
IPO registration
5:03pm
S-1
EX-10.11
qpso2esj0cfcrl1ns8gl
25 Aug 23
IPO registration
5:03pm
S-1
EX-10.14
9gbciwd35j ta7z
25 Aug 23
IPO registration
5:03pm
S-1
EX-3.4
kqnxjrf1
25 Aug 23
IPO registration
5:03pm
S-1
EX-10.10
l9rf4raw239
25 Aug 23
IPO registration
5:03pm
S-1
EX-10.16
h561gbojf w8lu6he
25 Aug 23
IPO registration
5:03pm
S-1
EX-10.18
w1l9h
25 Aug 23
IPO registration
5:03pm
S-1
EX-10.20
fpvmhncqaxuti3ojqhi
25 Aug 23
IPO registration
5:03pm
S-1
EX-10.1
q6ag9ujoteiob4nces2
25 Aug 23
IPO registration
5:03pm
S-1
EX-10.9
nxwhkl
25 Aug 23
IPO registration
5:03pm
S-1
EX-10.19
tm6g9t8yomhcq
25 Aug 23
IPO registration
5:03pm
S-1
EX-10.15
x1y6hne
25 Aug 23
IPO registration
5:03pm